Price (delayed)
$2.245
Market cap
$6M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$34.4
Enterprise value
$70.21M
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically
There are no recent dividends present for BTAI.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from and Sharadar.